Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Guerbet Board/Management Information 2011

Jun 9, 2011

1392_iss_2011-06-09_17b7c70d-e512-4838-b977-99a228fe8cbe.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

P R E S S R E L E AS E

Jean-Jacques Bertrand, Chairman & CEO of Guerbet

Villepinte, June 9, 2011

Following the death of Bernard Massiot, CEO of the Guerbet group, Jean-Jacques Bertrand agreed at a Board meeting held today (June 9) to take up the position of CEO in addition to his position of Chairman of the Board of Directors, during the period required to recruit a new CEO.

As the positions of Chairman of the Board and CEO are no longer dissociated, Jean-Jacques Bertrand consequently temporarily assumes the title of Chairman & CEO of Guerbet.

Jean-Jacques Bertrand worked closely with Bernard Massiot and he undertakes, with the board of directors and the management team, to ensure the continuity of the work undertaken and will make it his duty to respect the spirit of his work to enable Guerbet pursue its ambition of being a major player in medical imaging.

Bernard Massiot became a director of the company in 1993, then vice-chairman of the supervisory board, becoming its CEO in January 2010.

About Guerbet

Guerbet is the only pharmaceutical group totally dedicated to medical imaging on the world market. It has a comprehensive range of X-ray, MRI and nuclear medicine imaging products to enhance overall patient care. Its products facilitate diagnosis and the preparation of treatment strategies for major pathologies (cardiovascular diseases, cancers, inflammatory and degenerative diseases).

To discover new products and ensure its future development, Guerbet devotes significant resources to R&D every year: 210 staff and a sum equivalent to 11% of its sales. The programs on MRI and nuclear medicine modalities are central to Guerbet's research priorities.

Guerbet has a very strong presence in Europe with a market share of 25% and is developing its presence in the United States, South America and Asia.

Guerbet, listed on the Euronext Paris Eurolist (compartment B), posted sales of €352 million in 2010 with a total headcount of 1300.

For more information about Guerbet, please go to www.guerbet.com.

Press contacts: Anne-Laure Delasalle, VP Communications & Image

Tel: 01 45 91 50 03

[email protected]